Klotho gene G395A and C1818T polymorphisms in acromegaly:

pay.thelady61 shared this article with you from Inoreader Klotho gene G395A and C1818T polymorphisms in acromegaly: Association with clinical presentation and comorbidities Via Clinical Endocrinology Abstract Background Klotho is a new identified anti‐ageing gene with tumour suppressor activities. Current data suggest that there is a tight relationship between Klotho protein and growth hormone (GH)/insulin‐like growth factor‐1 (IGF‐1) axis. Purpose This study aimed to investigate the possible association of Klotho gene polymorphisms with acromegaly and to assess whether these polymorphisms contribute to clinical characteristics, comorbidities and biochemical variables in these patients. Methods The study included 52 patients with acromegaly and 52 unrelated healthy subjects. The Klotho G395A and C1818T polymorphisms were assessed by Sanger sequencing. Serum levels of sKlotho were determined by ELISA method. Results Subjects carrying GA genotype of Klotho G395A polymorphism had 3.27 times higher risk of developing acromegaly [odds ratio (OR), 3.27; 95% confidence interval (CI): 1.37–7.81; p = .023]. The A allele of G395A was significantly associated with acromegaly risk (OR, 2.27; 95% CI: 1.1–4.72; p = .022). No association was observed between the studied polymorphisms and disease characteristics including age at acromegaly diagnosis, size of adenoma, baseline GH and IGF‐1 concentrations, and final outcome. G395A polymorphism was associated with the presence of malignancy (OR, 2.24, 95% CI: 1.63–3.08; p = .019) and colorectal polyps (OR, 1.99; 95% CI: 1.02–3.88; p = .047) in patients with acromegaly. Serum sKlotho levels were significantly higher and correlated with GH and IGF‐1 levels among acromegaly patients. There was no association between the studied polymorphisms and sKlotho levels. Conclusions Klotho G395A polymorphism is associated with acromegaly susceptibility and increased risk of malignancy and colorectal polyps in these patients. View on the web Inoreader. Take back control of your news feed. Follow us on Twitter and Facebook.